GenScript Biotech Corporation has officially opened its first European mRNA production site in Delft, the Netherlands, marking a major expansion of the company’s global mRNA platform. This facility positions Europe as a key component of GenScript’s integrated research and production network, enabling local access to advanced mRNA capabilities while maintaining global standards.
The new Delft site enhances transatlantic biotech infrastructure by providing closer proximity to European innovators, aligning with local regulatory frameworks, and improving supply chain resilience. This ensures faster project turnaround and smoother collaboration for researchers developing next-generation therapies, vaccines, and advanced biologics.
“Having a local GenScript facility in the EU makes a real difference for us,” said Paula Río, PhD, Hematopoietic Innovative Therapies Unit, CIEMAT/CIBERER/FJD, UAM. “We benefit from seamless collaboration, faster processing times, and reduced shipping delays. Working with a team fully aligned with EU regulations strengthens the partnership and simplifies daily interactions.”
Strengthening a Global Platform
Founded over two decades ago in New Jersey, GenScript has steadily expanded its innovation footprint across North America and Europe. The Delft facility reflects the company’s platform strategy: integrating global capabilities into regionally embedded, customer-ready infrastructure.
“Europe is not just an outpost; it is a core pillar of our global mRNA platform,” said Shawn Wu, President of GenScript EU Division. “By incorporating Delft into our unified operating system, we deliver faster service, regulatory alignment, and operational resilience while maintaining one uncompromising global standard.”
The facility offers end-to-end mRNA workflow capabilities, including:
It operates within GenScript’s AI-enabled digital framework, supporting consistent processes, faster turnaround times, and seamless integration with the company’s global R&D and manufacturing network.
Regional Innovation Meets Global Integration
Aligned with EU regulatory standards yet fully integrated into global quality systems, the Delft hub enables clients to efficiently progress from research-grade mRNA to downstream development. This expansion complements GenScript’s growing U.S. operations, including its New Jersey campus, and is part of a coordinated strategy to build resilient, high-quality platforms for life science innovation from discovery through advanced development.
GenScript’s mRNA capabilities form part of a broader integrated biotech ecosystem, supporting the journey from scientific idea to impactful therapy.
Supporting Europe’s Biotech Growth
Since establishing its European Division headquarters in the Netherlands in 2021, GenScript has steadily scaled regional operations. The Delft site strengthens local access to advanced mRNA technologies while maintaining global reach.
“GenScript has demonstrated commitment to innovation, collaboration, and scientific excellence,” said Cindy Gerhardt, Managing Director of Planet B.io. “This state-of-the-art lab reinforces the position of Biotech Campus Delft, benefiting both our community and the broader European biotech ecosystem.”
Sherry Shao, CEO of GenScript Biotech Corporation, adds: “This expansion exemplifies disciplined execution of our global platform strategy. Investing in resilient, regionally anchored infrastructure allows science to move confidently from discovery to development across regions, at scale.”
The Delft expansion is part of GenScript’s long-term plan to build scalable, automation-driven biotechnology platforms worldwide. The facility is designed to support high-quality, integrated workflows that accelerate scientific discovery and therapeutic development.
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare, providing researchers and companies with essential tools to develop groundbreaking treatments. Operating across more than 100 countries, with a team of 5,500+ employees, GenScript supports over 200,000 customers, including the world’s top 20 pharmaceutical companies. Its mission is to make people and nature healthier through biotechnology.
Convenience retail is becoming an increasingly data-driven business, with operators balancing tight margins, shifting consumer…
As enterprises have moved more workloads into virtualised environments, the hypervisor has become a critical…
Rally Saudi Arabia will not form part of the 2026 FIA World Rally Championship due…
Outdoor footwear is increasingly expected to do more than perform on a trail. Consumers move…
The non-alcoholic beverage market is beginning to move beyond the simple promise of drinking less.…
For clean-energy technology companies, sustainability reporting is increasingly moving beyond a compliance exercise. Investors, customers…